Market Overview:
The global hospital-treated gram-negative infections market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of hospital-acquired infections, growing demand for novel antibiotics, and rising awareness about nosocomial infections. Based on type, the global hospital-treated gram-negative infections market is segmented into Klebsiella, Acinetobacter, Coli, cepacia, Pseudomonas, Serratia, Enterobacter and others. Klebsiella is the most commonly reported type of bacteria causing healthcare associated pneumonia (HAP) and account for nearly one third of all HAP cases in Europe. In terms of application, the global hospital-treated gram negative infection market is segmented into hospitals and laboratories.
Product Definition:
A hospital-treated gram-negative infection is an infection that is treated in a hospital. This type of infection can be serious and may require antibiotics or other treatments.
Klebsiella:
Klebsiella is a gram-positive bacteria that lives in the gut and on the skin. It causes granulomatous infections, which are usually found in the lungs, liver or kidneys. The most common symptoms include abdominal pain, diarrhea and vomiting. Some people may also experience fatigue, shortness of breath and blood streaming from their stool or urine.
Acinetobacter:
Acinetobacter is a gram-negative bacteria that can cause bacteremia and fungemia. It can also cause pneumonia, bloodstream infections, and ventilator-associated pneumonia (HABP/VABP). The most common sites of infection are the lungs, urinary tract, bones, skin lesions or wounds.
Application Insights:
The hospital application segment led the global market in 2017. The segment is expected to expand at a CAGR of XX% over the forecast period owing to an increase in healthcare facilities at a global level and increasing awareness about GNGI across all regions, especially in developing countries like India and China.
In addition, factors such as rising prevalence of chronic diseases along with high patient admissions due to an increase in geriatric population are anticipated to drive the demand for hospitals over the forecast period. In addition, governments around the world are making efforts towards improving healthcare infrastructure by building more hospitals which will further fuel growth during future years.
Regional Analysis:
North America dominated the global hospital-treated Gram-negative infections market in 2017. This can be attributed to factors such as the presence of well-established healthcare infrastructure, high patient awareness levels coupled with a quick adoption of technologically advanced treatment procedures and medicines. Moreover, rising initiatives by private and public organizations to raise funds for research & development activities is expected to fuel growth over the forecast period.
Asia Pacific is estimated to witness lucrative growth during the forecast period owing to increasing government spending on healthcare facilities along with an increase in investments by various pharmaceutical companies for R&D purposes pertaining Gram negative bacteria infection management strategies. In addition, favorable government policies aimed at improving access and quality of care are anticipated boost regional market growth during the forecast period (2018 - 2030).
Growth Factors:
- Increasing incidence of hospital-treated gram-negative infections due to the growing prevalence of multi-drug resistant bacteria strains.
- Rising demand for novel antibiotics and rapid diagnostic tests for effective treatment of hospital-treated gram-negative infections.
- Growing number of mergers and acquisitions among key players in the hospital-treated gram-negative infections market to expand their product portfolios and strengthen their market positions.
- Proliferation of private healthcare sector across emerging economies that is expected to increase the demand for hospital treated gram negative infection therapies and diagnostics over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hospital-Treated Gram-Negative Infections Market Research Report
By Type
Klebsiella, Acinetobacter, Coli, cepacia, Pseudomonas, Serratia, Enterobacter, Others
By Application
Hospital, Lab
By Companies
Merck, Pfizer, AstraZeneca, Abbott, Lupin Pharmaceuticals, Istituto lusofarmaco d’italia, Adelco S.A, Zhejiang yuntao biotechnology co., Ltd, Alcon Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
209
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Hospital-Treated Gram-Negative Infections Market Report Segments:
The global Hospital-Treated Gram-Negative Infections market is segmented on the basis of:
Types
Klebsiella, Acinetobacter, Coli, cepacia, Pseudomonas, Serratia, Enterobacter, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Lab
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Pfizer
- AstraZeneca
- Abbott
- Lupin Pharmaceuticals
- Istituto lusofarmaco d’italia
- Adelco S.A
- Zhejiang yuntao biotechnology co., Ltd
- Alcon Laboratories
Highlights of The Hospital-Treated Gram-Negative Infections Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Klebsiella
- Acinetobacter
- Coli
- cepacia
- Pseudomonas
- Serratia
- Enterobacter
- Others
- By Application:
- Hospital
- Lab
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hospital-Treated Gram-Negative Infections Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hospital-treated gram-negative infections are infections that are treated in a hospital setting. This includes both bacterial and fungal infections.
Some of the major companies in the hospital-treated gram-negative infections market are Merck, Pfizer, AstraZeneca, Abbott, Lupin Pharmaceuticals, Istituto lusofarmaco d’italia, Adelco S.A, Zhejiang yuntao biotechnology co., Ltd, Alcon Laboratories.
The hospital-treated gram-negative infections market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hospital-Treated Gram-Negative Infections Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hospital-Treated Gram-Negative Infections Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hospital-Treated Gram-Negative Infections Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hospital-Treated Gram-Negative Infections Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hospital-Treated Gram-Negative Infections Market Size & Forecast, 2020-2028
4.5.1 Hospital-Treated Gram-Negative Infections Market Size and Y-o-Y Growth
4.5.2 Hospital-Treated Gram-Negative Infections Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Klebsiella
5.2.2 Acinetobacter
5.2.3 Coli
5.2.4 cepacia
5.2.5 Pseudomonas
5.2.6 Serratia
5.2.7 Enterobacter
5.2.8 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Lab
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hospital-Treated Gram-Negative Infections Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hospital-Treated Gram-Negative Infections Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Klebsiella
9.6.2 Acinetobacter
9.6.3 Coli
9.6.4 cepacia
9.6.5 Pseudomonas
9.6.6 Serratia
9.6.7 Enterobacter
9.6.8 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Lab
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Klebsiella
10.6.2 Acinetobacter
10.6.3 Coli
10.6.4 cepacia
10.6.5 Pseudomonas
10.6.6 Serratia
10.6.7 Enterobacter
10.6.8 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Lab
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Klebsiella
11.6.2 Acinetobacter
11.6.3 Coli
11.6.4 cepacia
11.6.5 Pseudomonas
11.6.6 Serratia
11.6.7 Enterobacter
11.6.8 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Lab
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Klebsiella
12.6.2 Acinetobacter
12.6.3 Coli
12.6.4 cepacia
12.6.5 Pseudomonas
12.6.6 Serratia
12.6.7 Enterobacter
12.6.8 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Lab
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Klebsiella
13.6.2 Acinetobacter
13.6.3 Coli
13.6.4 cepacia
13.6.5 Pseudomonas
13.6.6 Serratia
13.6.7 Enterobacter
13.6.8 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Lab
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hospital-Treated Gram-Negative Infections Market: Competitive Dashboard
14.2 Global Hospital-Treated Gram-Negative Infections Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Pfizer
14.3.3 AstraZeneca
14.3.4 Abbott
14.3.5 Lupin Pharmaceuticals
14.3.6 Istituto lusofarmaco d’italia
14.3.7 Adelco S.A
14.3.8 Zhejiang yuntao biotechnology co., Ltd
14.3.9 Alcon Laboratories
